Clinical trial · Observational
Cancer Stem Cells in Multiple Myeloma
Flow Cytometric Definition and Prognostic Effects of Multiple Myeloma Cancer Stem Cells
NCT01820546CI-TRIAL-00020446completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
In multiple myeloma "cancer stem" cells can be defined and quantified with flow cytometry. More, these cells can be related to treatment response.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Multiple Myeloma | Multiple Myeloma | CURATED_EXACT | 0.92 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Treatment Response
- timeFrame
- 3 months
- description
- After 3 courses chemotherapy treatment response
Secondary outcomes (1)
- measure
- Treatment Response
- timeFrame
- 6 months
- description
- After 6 courses chemotherapy treatment response
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * New Diagnosed or Relapsed Multiple Myeloma * Routine Bone Marrow Aspiration will be done Exclusion Criteria: * Bone Marrow Aspiration is not Needed
References
Publications (1)
- BACKGROUNDMatsui W, Huff CA, Wang Q, Malehorn MT, Barber J, Tanhehco Y, Smith BD, Civin CI, Jones RJ. Characterization of clonogenic multiple myeloma cells. Blood. 2004 Mar 15;103(6):2332-6. doi: 10.1182/blood-2003-09-3064. Epub 2003 Nov 20. PMID 14630803